Hanmi Pharmaceutical's Pyeongtaek manufacturing center, a global biopharmaceutical production base, has received the highest rating in the Process Safety Management (PSM) evaluation conducted by the Ministry of Employment and Labor. The Pyeongtaek facility is a key site for producing the obesity treatment drug 'efegleneratide,' which is set to launch in the second half of this year, and has once again been recognized by the government for its safety management system and capabilities.
On July 31, Hanmi Pharmaceutical announced that its Pyeongtaek manufacturing center achieved the top rating of 'P grade' in the regular PSM evaluation conducted by the Ministry of Employment and Labor this year.
Following its initial P grade in 2022, the Pyeongtaek manufacturing center has maintained this top rating, becoming the first in the pharmaceutical and biopharmaceutical industry to achieve a consecutive P grade.
The PSM evaluation is a system that comprehensively assesses the safety management level of workplaces handling hazardous materials and equipment to prevent major industrial accidents. Based on the evaluation results, ratings are assigned as P (excellent), S (good), M+ (average), and M- (poor).
The P grade signifies the highest level of safety management recognized by the government. As of 2025, only 26 out of 614 workplaces in the metropolitan area have received this rating, reflecting the strict evaluation criteria that require a stable autonomous safety management system to be in place throughout the facility.
The Pyeongtaek manufacturing center has continuously operated its safety management system, focusing on advanced risk assessments, proactive identification of hazardous factors, enhanced on-site safety activities, and the promotion of a safety culture. It received high marks for successfully establishing the PSM system through employee participation in preventive safety management activities.
By maintaining the P grade, the Pyeongtaek manufacturing center has been recognized as a facility where an autonomous safety management system, from risk identification to preventive and improvement activities, is firmly established across the organization.
Hanmi Pharmaceutical is continuously strengthening its environmental, health, and safety (EHS) management systems, particularly at its key sites, including the Pyeongtaek and Palttan manufacturing centers. The company stated that it is securing a global-level safety management system and production competitiveness through data-driven safety management activities and a preventive-focused operational system.
Kim Se-gwon, head of the Pyeongtaek manufacturing center at Hanmi Pharmaceutical, stated, "Achieving the PSM top rating for the second consecutive time is the result of all employees prioritizing 'safety' as the foremost value and consistently practicing it. We will continue to strengthen proactive risk management and systematic safety management activities to create a zero-accident workplace and enhance our global competitiveness based on a safe production environment."
Meanwhile, Hanmi Pharmaceutical reported preliminary consolidated results for the second quarter of 2026, with sales of 467.2 billion won and an operating profit of 131.1 billion won.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.